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ABSTRACT: The balance of pro-apoptotic and pro-survival proteins deﬁnes a cell’s fate. These processes are controlled through an
interdependent and ﬁnely tuned protein network that enables survival or leads to apoptotic cell death. The caspase family of
proteases is central to this apoptotic network, with initiator and executioner caspases, and their interaction partners, regulating and
executing apoptosis. In this work, we interrogate and modulate this network by exogenously introducing speciﬁc initiator or
executioner caspase proteins. Each caspase is exogenously introduced using redox-responsive polymeric nanogels. Although caspase3 might be expected to be the most eﬀective due to the centrality of its role in apoptosis and its heightened catalytic eﬃciency
relative to other family members, we observed that caspase-7 and caspase-9 are the most eﬀective at inducing apoptotic cell death. By
critically analyzing the introduced activity of the delivered caspase, the pattern of substrate cleavage, as well as the ability to activate
endogenous caspases, we conclude that the eﬃcacy of each caspase correlated with the levels of pro-survival factors that both directly
and indirectly impact the introduced caspase. These ﬁndings lay the groundwork for developing methods for exogenous introduction
of caspases as a therapeutic option that can be tuned to the apoptotic balance in a proliferating cell.
KEYWORDS: intracellular protein delivery, caspase, intrinsic and extrinsic apoptosis, stimuli-responsive materials, nanogels

■

INTRODUCTION
Mutations that block apoptotic cell death accumulate in most
cancers, leading to chemoresistance, tumorigenesis, and metastasis.1 Inducing apoptosis for cancer therapy is a powerful
therapeutic strategy, but targeting the appropriate point in the
balance between cell death and survival is critical. The apoptotic
cascade uses caspases (cysteine aspartate proteases; casp)
centrally to cleave a series of substrates resulting in cell death.
Apoptotic caspases are classiﬁed as either upstream initiator
(casp-8 and -9) or downstream executioner (casp-3, -6, and -7),
depending on their mechanism and point of activation2
(Scheme 1). Caspase activation is regulated by pro-survival
members of the B-cell lymphoma-2 (Bcl-2) family,3,4 and
caspase activity can be inhibited by inhibitors of apoptotic
proteins (IAPs).4,5 Due to their signiﬁcant role in apoptosis,
suppressed caspase function as well as pro-apoptotic and prosurvival protein imbalance contributes to apoptotic resistance.6
While virtually all cancers have developed means of evading
apoptosis, the mechanism of evasion diﬀers widely between
cancers. Thus, increasing the amount of an appropriate active
intracellular caspase to induce apoptosis in individual cancer
© 2021 The Authors. Published by
American Chemical Society

environments is a powerful therapeutic strategy, particularly
because caspases are inherently catalytic.
Casp-3 has undoubtedly been the most prevalent apoptotic
cargo for exogenous introduction, due to its known apoptotic
potency, which stems from a vast substrate pool and the most
eﬃcient substrate turnover of all caspases.7 However, because
each cancer has evolved a unique repertoire of blocks to
apoptosis, and because each caspase is subject to unique
regulation, it is plausible that the identity of the caspase that
would be most eﬀective at triggering cell death will depend
exquisitely on the unique repertoire of accumulated antiapoptotic mutations. In addition, after activation, the various
caspases show diﬀerent subcellular distribution among the
cytosol, nucleus, microsomes, or mitochondria8,9 due to their
Received: June 9, 2021
Published: July 8, 2021
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Scheme 1. Exogenous Introduction of Diﬀerent Apoptotic Caspases May Result in Unique Apoptotic Outcomesa

a

Apoptotic pathways are mediated by caspases, calling into question which exogenously introduced caspase will be most eﬀective at inducing cell
death. Initiators casp-8 and casp-9 are activated in response to extrinsic and intrinsic stimuli, respectively. After initiator caspase activation, the
executioners casp-3, -6, and -7 are activated, resulting in feedback activation of initiator caspases and direct substrate proteolysis, leading to cell
death. Caspase activity is inhibited by pro-survival factors which are overexpressed to various extents in various cancerous tissues. Example
executioner caspase substrates include poly(ADP-ribose) polymerase 1 (PARP-1), p23, and lamin A, colored to match the caspase that cleaves
them (i.e., red for casp-6, green for casp-7, and green/purple for casp-3 and -7). Exogenous introduction of each of the apoptotic caspases, via
nanogel intracellular delivery, allowed us to assess which caspase is best at cleaving cells of a given pro-survival proﬁle.

addition to serum-containing cell cultures facilitates examination of the apoptotic inducibility of diﬀerent caspases in cells
with diverse anti-apoptotic repertoires. Casp-8 and casp-9 are
initiators and are activated upstream in response to extrinsic or
intrinsic stimuli, respectively. In the extrinsic pathway,
extracellular death ligands (i.e., TRAIL, FasL, TNF-α) trigger
the recruitment of zymogen procasp-8 via death eﬀector domain
(DED) interactions to the death-inducing signaling complex
(DISC), leading to casp-8 activation.2 In the intrinsic pathway,
mitochondrial stress from internal triggers (i.e., sensing of
radiation, hypoxia, chemotherapeutics) facilitates the recruitment of procasp-9 via caspase activation and recruitment
domain (CARD) interactions to form the apoptosome,
activating casp-9.2 In contrast to the executioners, both casp-8
and casp-9 fail to be maximally activated solely by proteolysis or
dimerization, but are fully activated upon formation of multimer
protein−protein complexes, likely due to induced proximitymediated activation.31,32 Activation of both casp-8 or casp-9
converges in proteolysis of executioner procasp-3 and -7 at their
inter-subunit linker (ISL). This cleavage generates the mature,
active casp-3 and -7. The presence of active casp-3 and -7 results
in procasp-6 cleavage and activation.33−36 Importantly, upon the
activation of the executioner caspases, the intrinsic and extrinsic
pathways cross-talk, leading to signal ampliﬁcation as casp-3 can
process procasp-937 and casp-6 can directly activate procasp-8.38
Procaspase activation pathways upon intrinsic35,39,40 and
extrinsic41−43 stimuli, caspase feedback loops,34,36,44 and
caspase−procaspase proteolysis in vitro45,46 have been thoroughly investigated (Scheme S1).33−42 These features highlight

diﬀerential cleavage of elements that control organelle entry.
Thus, the ideal caspase for inducing apoptosis in various cancers
must be individually evaluated.
The eﬃcacy of introducing exogenous casp-3 has been
investigated by our group using redox-responsive polymeric
materials10,11 and others via assorted materials including
peptides,12 lipids,13 dendrimers,14 polymers,15 and inorganics.16−18 Similarly, casp-3 and casp-9 have been exogenously
introduced to cells using gene therapies.19−21 Introducing the
native human casp-3 gene encoding procaspase-3 zymogen has
been found to be unproductive without an apoptosis inducer,20
which is not surprising. To circumvent this, genes encoding a
constitutively active, non-native casp-3 are required for any
apoptotic eﬃcacy.21 Gene therapies for an inducible casp-9 have
also generated interest, but again, they require cell-permeable
molecules for activation,22 are enhanced with apoptosis
inducers,23 and require tissue-speciﬁc promoters to achieve
cell-speciﬁc expression.19,24 In addition, delivering cytochrome c
leads to signiﬁcant caspase-mediated cell death by stimulating
apoptosome formation, suggesting there is merit to fully explore
delivery of activated caspases.25−27
Here, we utilize redox-responsive polymeric nanogels (NGs)
as an accessible biochemical tool to exogenously introduce
active casp-3, -6, -7, -8, or -9 into live cells, requiring preparation
of only two components: recombinant puriﬁcation of the
caspase of interest and synthesis of the delivery polymer. The
polymer used herein,10 as well as other derivatives,26,28−30 has
been previously reported for a myriad of cargo. After a facile
aqueous reaction and puriﬁcation, caspase NG (casp-NG)
1241
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Figure 1. Apoptotic caspase constructs used. (A) Cartoons representing the linear sequence of caspases. Generally, caspase constructs contain a Nterminal prodomain followed by a large subunit, intersubunit linker (ISL), and small subunit as well as a hexahistidine (H6) tag. Gray arrows and
corresponding aspartic acid residues represent cleavage sites. Constitutively two-chain (CT) casp-6 does not contain a prodomain nor ISL. (B)
Cartoons reﬂecting caspase self-processing. Large subunits are represented in the dark shade and small subunits in the light shade. (C) Oligomeric
caspase structures with cysteine residues highlighted as yellow spheres. Each of the monomers, which are composed of one large and one small subunit
after cleavage at the ISL, are drawn in a diﬀerent shade. PDB IDs: casp-3 (2C2O), casp-6 (3K7E), casp-7 (3IBF), casp-8 (2C2Z), casp-9 (1JXQ). (D)
Total number of caspase cysteine residues. (E) Total number of solvent-exposed cysteine residues calculated using Ellman’s reagent on two separate
days. (F) Tabulated molecular weights of caspase subunits in the constructs used.

overexpressed full-length procaspase-3, -7, -8, and -9 zymogens
self-proteolyze, generating the large and small subunits and the
properly formed substrate binding groove of the active caspase
(Figure 1B). CT casp-6 expresses the large and small subunits
independently, mimicking native activation by cleavage.51 The
canonical dimer-of-dimers (heterotetramer) caspase structure is
conserved in all caspases (Figure 1B,C), although casp-8 exists
as a monomer/dimer mixture52 and casp-9 exists primarily as a
monomer prior to binding substrate.53 The apoptotic caspases
each contain 8−13 cysteines, comprising 3−3.5% of total
sequence (Figure 1C,D), with 5−6 thiols solvent exposed
(Figure 1E) in each similarly sized caspase (Figure 1F). Thus,
delivery vehicle formulation using thiol chemistry is feasibly
possible for all caspases as cargo.

the fact that the network by which each caspase might
independently induce cell death is distinct.47 Our ability to
deliver diﬀerent caspases oﬀers a unique opportunity to evaluate
the impact of exogenous caspase introduction on cellular fate.
Moreover, the synchronized activation of executioners casp-3,
-6, and -7 leads to cleavage of protein substrates critical to
intracellular function and cell structure, irreversibly sentencing a
cell to death.48 Casp-3 and -7 share some biochemical similarity
as they are observed to recognize the same cleavage motif
(DEVD) but are functionally distinct with both overlapping and
non-overlapping substrate pools.40,45 Removal of both enzymes
together demonstrates signiﬁcant resistance to apoptosis upon
both intrinsic or extrinsic stimuli, underlying merit for
subsequent casp-7 delivery investigation.36 Casp-6 has canonically been characterized as an apoptosis executioner,38 with
tumor-associated cancer mutations,49 but its removal has no
signiﬁcant eﬀect on apoptosis.36 Overall, this study takes a
concerted approach to understanding the consequence of
polymeric nanogel-based exogenous introduction of diﬀerent
caspases on cellular apoptosis (Scheme 1).

Caspases Can Be Stably Encapsulated in PEG−PDS
Polymers to Form Casp-NGs

For exogenous introduction of caspases, a compatible delivery
vehicle formulation is clearly essential. Our group has created
redox-responsive polymers capable of casp-3 encapsulation
without any irreversible modiﬁcation of the protein surface.10
The amphiphilic random copolymers used here are composed of
polyethylene glycol (PEG) and pyridyl disulﬁde (PDS), the
hydrophilic and hydrophobic units, respectively (Figure 2A). In
aqueous media, PEG−PDS polymers self-assemble into
aggregates that can be cross-linked with a reducing agent (e.g.,
DTT) to stabilize the nanomaterial.54 During the polymer selfassembly stage, casp-3 is easily encapsulated via reaction of casp3’s solvent-exposed cysteine residues with polymer PDS units
(Figure 2A). Upon NG cellular uptake and endosomal escape,

■

RESULTS AND DISCUSSION
To harness the power of any caspase to induce apoptosis in cells
into which they are exogenously introduced, it is important that
they are intracellularly delivered in their mature and active
forms. For this reason, we used constructs that all produce active
(cleaved) caspases: full-length wild-type (WT) casp-3, constitutively two-chain (CT) casp-6, full-length WT casp-7,
ΔDED casp-8 (with improved solubility and lower aggregation),50 and full-length WT casp-9 (Figure 1A). Bacterially
1242
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Figure 2. Apoptotic casp-NG formation and characterization. (A) Dissolving amphiphilic PEG−PDS polymers in aqueous milieu results in
nanoaggregates that can be cross-linked into stable nanogels by a reducing agent, such as dithiothreitol (DTT). To generate casp-3 NG, casp-3 is added
to the aqueous PEG−PDS solution prior to cross-linking. (B) Substituting the diﬀerent apoptotic caspases in place of casp-3 allows generation of the
caspase nanogel (casp-NG) series. (C) Casp-NGs are prepared to ensure formation of similar NG. The degree of cross-linking is quantiﬁed by
absorbance of pyridine-2-thiol at 343 nm. (D) Casp-NG size distribution. Data show the average of three technical replicates. (E) Casp-NG protein
encapsulation and release visualized by comparing caspase subunit intensities using nonreducing and reducing conditions for SDS-PAGE.

demonstrated signiﬁcantly more activity (256 ± 31% and 162 ±
11%, respectively) than their free counterparts (Figure 3B,C).
Free casp-6 and casp-7 controls showed signiﬁcant precipitation,
whereas casp-6 or -7 NG did not, suggesting that the reactive
self-assembly process protected the encapsulated cargo from
self-proteolysis and aggregation, as observed for casp-3.10 In
comparison, the initiators, casp-8 and -9, demonstrated minimal
proteolytic activity (7 ± 1% and 6 ± 6%, respectively) upon NG
release (Figure 3D,E). This loss in activity may be related to the
fact that the concentrations of the initiator caspases released
from NG are not suﬃcient to support their proximity-induced
activation,31,32 which is required to increase their inherently low
catalytic eﬃciencies (Table S1). Thus, we hypothesized that a
more catalytically active casp-9 variant, constitutively dimeric
casp-9 (casp-9cD),57 might retain more activity following NG
formation. Casp-9cD diﬀers from WT casp-9 by only ﬁve
residues, derived from the casp-3 dimerization interface, which
enables casp-9 cD to form an active dimer. 57 Casp-9 cD
demonstrated similar NG encapsulation and release to WT
casp-9 (Figure S2). However, NG-released casp-9cD demonstrated 6-fold more activity than NG-released WT casp-9 (36 vs

intracellular glutathione (GSH) simultaneously reduces the NG
cross-links and releases native casp-3, followed by presumed
degradation of the remaining material by endogenous esterases
(Figure 2A). The casp-NG series (Figure 2B) was generated as
previously described10 using a 1:25 caspase/polymer ratio, with
DTT-mediated cross-linking assessed by released pyridine-2thiol absorbance at 343 nm (Figure 2C).55 Monodisperse
nanomaterials of ∼10 nm were observed for all caspase cargos
(Figure 2D). Encapsulation eﬃciencies were comparable across
all cargos (Figure S1), and DTT-mediated release of apoptotic
casp-3, -6, -7, -8, and -9 was robustly observed (Figure 2E).
Casp-NG Formation Inﬂuences the Activity of Each Caspase
toward Peptide Substrates Distinctly

Eﬀective delivery of an enzyme like a caspase requires that both
encapsulation and release can be achieved without negatively
impacting enzymatic function. We assessed the eﬀect of NG
formation on the ability of released caspases to cleave a
ﬂuorogenic tetrapeptide substrate in a buﬀer optimized for each
caspase.56 Casp-3 maintains 80% activity (Figure 3A) of the free
casp-3 control.10 Comparatively, NG-released casp-6 and casp-7
1243
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Figure 3. Evaluation of NG-released caspase activity toward peptide and protein substrates. Left lane: NG-released apoptotic caspases demonstrate
varying levels of enzymatic activity toward canonical ﬂuorogenic peptide substrates, compared to similarly incubated free protein controls. Casp-NGs
were left intact (without DTT) or were added to reductant (with DTT) to facilitate protein release. (A) Casp-3 NG + 100 mM DTT demonstrated 79
± 6% (average ± SEM) activity of the free protein control toward the ﬂuorogenic peptide substrate DEVD-amc. (B) Casp-6 NG; 256 ± 31%; VEIDafc. (C) Casp-7 NG; 162 ± 11%; DEVD-amc. (D) Casp-8 NG; 7 ± 1%; LEHD-afc. (E) Casp-9 NG; 6 ± 6%; LEHD-afc. (F) Casp-9cD NG; 36 ± 3%;
LEHD-afc. All error bars correspond to SEM of three independent NG batches, made and tested on separate days. Western blots: NG-released
apoptotic caspases demonstrate cleavage of canonical protein substrates. Casp-NGs were left intact (without DTT) or were added to reductant (with
DTT) to facilitate protein release prior to incubation with cell lysates; cell lines include Jurkat T-lymphocytes, embryonic kidney (HEK) cells, and
mammary cancer cells (MDA-MB-231). (G) NG-released casp-3-induced cleavage of poly(ADP-ribose) polymerase 1 (PARP-1), full-length (FL)
casp-6, and p23 within 3 h. (H) NG-released casp-6-induced cleavage of substrates DVL3, lamin A, and DJ-1 within 1 h. (I) NG-released casp-7induced cleavage of substrates PARP-1, FL casp-3, and p23 within 1 h. (J) NG-released casp-8-induced cleavage of BH3 interacting domain death
agonist after 5 h in three cell lines; *indicates visible ladder (K) NG-released casp-8 also induced cleavage of PARP-1 and (L) executioner FL casp-3
over time. (M) NG-released casp-9-induced PARP-1 cleavage. Immunoblots represent one biological replicate.
1244
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Figure 4. All apoptotic caspases are delivered intracellularly by PEG−PDS NGs. Immunoblot analysis of HEK293T total cell lysate demonstrating
eﬃcient PEG−PDS-mediated delivery at diﬀerent time points. (A) Casp-3 NG, (B) Casp-6 NG, (C) Casp-7 NG, and (D) Casp-9 NG delivery
detected using anti-His6 antibodies. (E) Improved delivery of Casp-9 via cationic (orange circles) triarginine NG functionalization. (F) Amount of
casp-9cD protein delivered is comparable to that of casp-9. (G) Delivery of casp-8 detected using an anticleaved casp-8 antibody. (H) Normalized
intensity (caspase small subunit intensity/loading control intensity) of the various caspases at 1 mg/mL; error bars correspond to SEM of three
independent biological NG batches, made and tested on separate days. One-way ANOVA was performed against casp-3 NG, and no signiﬁcant (n.s.)
diﬀerences were found.

disassembly and protein release by endogenous glutathione in
cell lysates. Thus, all of the NG-released executioner caspases are
robustly capable of cleaving native protein substrates in the
cytoplasm.
The initiator caspases can also be functionally released from
the NG. NG-released casp-8 induced cleavage of known
caspase-8 substrate BH3 interacting domain death agonist
(BID)3,42 to tBID (truncated BID) in all three cell lysates tested
(Figure 3J). These data suggest that despite minimal peptidyl
substrate turnover by NG-released casp-8 (Figure 3D), initiator
casp-8 is capable of substrate proteolysis upon delivery. In fact,
casp-8’s activity might be expected to increase within the
biological context due to a shift to a predominately dimeric state,
although likely not via recruitment to the DISC, which requires
extracellular factors and DED domain interactions. Further, NGreleased casp-8 demonstrated processing of PARP-1 to an 89
kDa fragment at the site recognized by casp-3 or -7 but not at the
site cleaved by casp-8 which results in a 48 kDa fragement65
(Figure 3K). This observation suggests that NG-released casp-8
activated executioner procasp-3 or -7, which then cleaved PARP1. PARP-1 is a predominate substrate of casp-7 and a minor
substrate of casp-3, with cleavage rates of 20 and 0.4 (×105 M−1
s−1), respectively.66 Accordingly, procasp-3 activation by casp841 was visualized over time in HEK293T cells. This was similar
to the results for NG-released casp-6 (Figure 3L), which we
attribute to NG-released active casp-6 mediating a feedback
loop, activating procasp-8.38 Casp-9 and casp-9cD NGs also
induced PARP-1 cleavage in two cell lines (Figure 3M),
mirroring the enhanced cleavage induced by casp-9cD that was
observed for peptidyl substrates (Figure 3E vs 3F). These data
suggest that even though NG-released initiator caspases

6% respectively, Figure 3F). Hence, assessing WT casp-9 and
casp-9cD as therapeutic cargos may reveal diﬀerent apoptotic
outcomes and mechanisms upon initiator caspase delivery.
While it is clear that executioners casp-6 and -7 are protected by
NG formation, initiators casp-8 and -9 appear not to be when
assayed against peptide substrates that interact only with the
active site.
All NG-Released Apoptotic Caspases Demonstrate
Substrate Proteolysis in Lysates

Because caspases are known to rely on allosteric interactions,58
exosites,59,60 and other molecules to stimulate substrate
recognition and recruitment, it is critical that we evaluate NGreleased caspase activity with native substrates, in addition to the
synthetic peptides assessed above. To assess NG-released
caspase activity toward protein substrates in a biological context,
casp-NGs were kept intact or disassembled with DTT prior to
incubation with cell lysates (workﬂow in Figure S3). Consistent
with casp-3 NG-mediated cell death previously reported,10,61
NG-released casp-3 demonstrated cleavage of known apoptotic
substrates including poly(ADP-ribose) polymerase 1 (PARP1),45,62 full-length casp-6,51 and cochaperone p2345 in three
diﬀerent cell lines (Figure 3G). NG-released casp-6 demonstrated processing of known substrates including segment
polarity protein disheveled homologue (DVL3),60 α-tubulin,63
lamin A,60,64 and Parkinson’s Disease protein 7 (PARK7 or DJ1)60 (Figure 3H). NG-released casp-7 demonstrated cleavage of
known substrates PARP-1, full-length casp-3,64 and p2345
(Figure 3I). Notable substrate cleavage was observed in the
absence of exogeneous DTT for some NGs, i.e., PARP-1
cleavage by casp-7 NG ± DTT (Figure 3I). We hypothesize that
this cleavage, in the absence of DTT, is due to casp-NG
1245
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Figure 5. Casp-NG mediated cleavage of PARP-1 and DVL3 and cell death proﬁles. Immunoblot analysis of NG-treated cell lysates and resultant
poly(ADP-ribose) polymerase 1 cleavage over time. (A) Casp-3, casp-6, casp-7, and casp-9 NG induced PARP-1 cleavage in HEK293T cells. Time
course experiments were executed once for each casp-NG. (B) In a direct comparison, PARP-1 is cleaved most abundantly by casp-7 NG followed by
casp-3 NG in HEK293T cells. Full-length PARP-1∼115 kDa, cleaved ∼89 kDa. (C) PARP is cleaved in a dose-dependent manner by casp-7 NG in
HEK293T and MDA-MB-231 cells. Casp-NG induced PARP-1 cleavage experiments were executed in two biological replicates, with diﬀerent NGs
made and tested on diﬀerent days. (D) Segment polarity protein disheveled homologue is cleaved in a dose-dependent manner mostly by casp-6 NG in
HEK293T cells in two biological replicates; *indicates visible molecular weight marker. (E) Previously reported levels of pro-survival proteins: IAP
levels in HEK293T cells,68 IAP levels in MDA-MB-231 and A549 cells,69 and SMAC levels in all three cell lines.70 Labels depict protein levels related to
the calculated average (±): lower (−) or higher (+). (F) Quantiﬁcation of pro-survival protein levels in respective cell lines, normalized to α-tubulin
loading control. Two-way ANOVA preformed for signiﬁcance test. Casp-NG induced varying levels of cell death in all cell lines, with casp-7 emerging
as the most potent apoptotic cargo. (G) Relative casp-NG (1 mg/mL) cell death proﬁles were monitored in HEK293T, Jurkat, MDA-MB-231, and
A549 cells, measured using 7-AAD and normalized to empty NG controls. (H) Casp-7 NG induced apoptosis in a dose-dependent manner. All error
bars correspond to SEM of two independent NG batches, made and tested on separate days. (I) Casp-7 NG induced a signiﬁcant population of early
apoptotic (33 vs 7% empty NG) and late apoptotic/dead cells (15 vs 5%) measured with AnnexinV and DAPI. AnnexinV experiments were
biologically replicated, but data herein represent one biological replicate. (J) Casp-7 NG signiﬁcantly depletes GFP signal in HeLa-GFP cells,
indicating ample cell death. Data herein represent one biological replicate.

complexes for maximum substrate turnover, total cell lysate
proteolysis assays represent the full potential of NG-released
proteolytic activity within the cellular environment. These data

demonstrated low peptide substrate turnover in a test tube, NG
formation did not silence initiator caspase activity. Moreover, as
these proteases are known to require additional protein
1246
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Scheme 2. (A) Presumed Routes to Apoptosis upon Exogenous Introduction of Active Apoptotic Caspasesa and (B) Levels of
Pro-survival Factors That Regulate Caspases and Apoptosis, Such as XIAP,68 cIAP1,69 and Bcl-2,78 Vary Depending on Cancer
Type and Are Correlated with Clinical Chemotherapeutic Outcomesb

a

Introduced caspases (NG symbol) promote varying degrees of known apoptotic hallmarks (Scheme S1).33−43,41−43 These measured outcomes
include cleavage of substrates (PARP-1, DVL3) and activity of both initiator (LEHDase) and executioner (VIEDase, DEVDase) caspases (Table
S3). Knowledge of these diﬀerences combined with known diﬀerences in inhibition by modiﬁcations and pro-survival factors (pink box) leads to
these presumed routes. bThis provided a rationale for observed diﬀerences in apoptotic propensity between diﬀerent endogenously introduced
caspases.

(Cy5) tagging full-length, active-site-knockout caspases prior to
NG formation. The active-site knockouts were used so that
caspase-induced apoptosis did not confound evaluation of caspNG cellular uptake. Flow cytometry revealed that all caspases
were delivered in a similar dose-dependent manner (Figure S4).
To further visualize delivery in a ﬂuorescence-independent
assay, we immunoblotted for the delivered caspases monitored
by their His6-tags. In HEK cells, we visualized internalization of

convincingly demonstrate that both executioner and initiator
caspases can be released in a functional manner in the cytosol
and can cleave their native apoptotic substrates.
All Apoptotic Caspases Are Exogenously Introduced at
Comparable Protein Levels

Given that caspases are released in a functional manner in cell
lysates, we next assessed NG-mediated caspase delivery to intact
cells in culture. We ﬁrst evaluated delivery by ﬂuorescently
1247
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correlations with observed outcomes. Notably, we also tested
Jurkat T-lymphocytes, a leukemic representative suspension cell
line, where elevated IAP levels are reported to hinder leukemic
therapies.69
Casp-NG induced apoptosis was measured using 7-aminoactinomycin D (7-AAD) (Figure S6).79,80 In HEK293T cells,
the amount of apoptosis induced by casp-6 and casp-9 NGs was
similar to that of casp-3 NG (Figure 5G). As predicted by the
extensive PARP-1 cleavage induced by casp-7 NG (Figure 5A−
C), casp-7 NG induced the most cell death of all casp-NGs
(Figure 5G). Similarly, consistent with the lack of activity and
substrate cleavage observed by casp-8 NG, this nanomaterial
failed to induce noticeable apoptosis compared to empty NG
controls (Figure 5G). Thus, we observed some correlation
between substrate cleavage and induced cell death in HEK293T
cells, which are reported to have the lowest protein levels of IAPs
(Figure 5E,F) and, thus, were the most susceptible to cell death.
In contrast, the cell death proﬁles observed for casp-3, -7, and -9
appeared to reﬂect a diﬀerent cellular apopototic context, with
casp-7 NG inducing the most apoptosis overall. MDA-MB-231
cells are reported to have higher levels of XIAP (Figure 5E,F),
and delivery of casp-3, -7, and -9 was less eﬃcient at inducing
apoptotic cell death than in other cell lines (Figure 5G). On the
other hand, casp-6 is not inhibited by XIAP but is also less
eﬃcacious at inducing apoptosis in MDA-MB-231 cells,
suggesting that other apoptotic regulators may also be in play.
Together, these data support the idea that the levels of antiapoptotic factors, particularly XIAP, present in a given cell type
have an ability to modulate caspase-induced cell death.
Delivered casp-7 and casp-9cD were the most eﬃctive at
inducing apoptosis. Casp-7-NG-mediated apoptosis was
observed by 7-AAD in a dose-dependent manner (Figure 5H)
and by AnnexinV staining of 48% of cells (Figure 5I). Consistent
with the increased catalytic activity of casp-9cD, ∼2-fold more
apoptosis and 79% AnnexinV positive cells were observed upon
casp-9cD NG treatment relative to casp-9 NG (Figure S7).
Finally, casp-7 NG treatment of cells stably expressing GFP (i.e.,
HeLa expressing destabilized GFP, HeLa-deGFP81) signiﬁcantly decreased GFP signal (Figure 5J), suggesting eﬃcient
induction of apopototic cell death.82 A redox-controlled casp-7
(casp-7HC)83 also eﬀectively induced PARP-1 cleavage and cell
death upon exogenous introduction (Figure S8). Together,
these data demonstrate that the diﬀerent apoptotic caspases,
including those with intrinsically slower rates of proteolysis than
casp-3, can be eﬀectively delivered to induce apoptosis. We
hypothesize that their eﬃcacy could be due to the cooperation of
unique mechanisms including the ability of each caspase to
tolerate NG formation, the signiﬁcance of substrates cleaved, the
repertoire of anti-apoptotic factors expressed that impact each
caspase, as well as feedback for activation of other procaspases.

active casp-3 after 8 h at two diﬀerent doses (Figure 4A).
Delivered active casp-6, casp-7, casp-9, and casp-9cD were
observed at similar levels (Figure 4B−D,F). We have previously
reported that functionalization of casp-3 NG with a triarginine
peptide (R3) resulted in an increase in the total amount of
protein delivered.10,61 Here, we likewise observed that upon R3
addition to casp-9 NGs, the delivery eﬃciency of casp-9
increased (Figure 4E). Casp-8 delivery was also observed in
multiple cell lines in a dose-dependent manner (Figure 4G and
Figure S5), but due to the failure of casp-8 detection using the
His6 antibody, we used a highly speciﬁc casp-8 antibody.
Delivery of all caspases fell within a 2-fold range and is not
statistically signiﬁcantly diﬀerent (Figure 4H), strongly
supporting our conclusion that delivery is independent of the
identity of the caspase cargo.
Exogenously Introduced Casp-7 Emerges as Most Eﬀective
Apoptosis-Inducing Cargo

Upon conﬁrming that detectable levels of protein were
delivered, we then assessed various apoptotic markers upon
delivery of the diﬀerent caspases in cells. Cells undergoing
apoptosis display a multitude of time-dependent morphological
and biochemical changes such as cell shrinkage, loss of plasma
membrane integrity, and PARP-1 cleavage62 to indicate faulty
DNA repair during chromatin degradation, facilitating nuclear
disintegration.67 We observed signiﬁcant cleavage of PARP-1 by
casp-3, -6, -7, and -9 NGs but not casp-8 NG within 8 h (Figure
5A). However, in a direct comparison, the amount of PARP-1
cleaved by casp-7 NG overshadowed the amount cleaved by the
other caspases (Figure 5B). PARP-1 cleavage induced by casp-7
NG was observed in a dose-dependent manner in two cell lines
(Figure 5C). As PARP-1 is a substrate of casp-3 and -7,45 casp-3
or -7 NG facilitated rapid cleavage of the delivered cargo’s direct
substrate (Scheme S1 and Scheme 2). On the other hand, casp-6
or -9 NG may induce indirect cleavage of PARP-1 via diﬀerent
mechanisms: delivered casp-9 may directly activate procasp-3 or
-7,35,39,40 while casp-6 may activate procaspase-3 directly44,46 or
procaspase-8,38,35 thus leading to casp-3 and -7 activation
(Scheme S1 and Scheme 2). Additionally, cleavage of the casp-6
substrate DVL360 was most signiﬁcant with casp-6 NG but was
also observed with casp-3 NG (Figure 5D). These data
demonstrate speciﬁc substrate turnover by executioner casp-3,
-6, and -7 in cellulo upon NG delivery.
We anticipated that caspase activity (e.g., PARP-1 cleavage) in
cells should correlate with the ability of delivered caspases to
induce cell death. Importantly, to understand the role of the
cellular apoptotic balance in cell death mediated by caspaseNGs, we evaluated casp-NG-mediated cell death in cell lines
with diﬀerent pro-survival and pro-apoptotic protein equilibria
(Scheme 2B). Speciﬁcally, protein levels of two IAPs, X-linked
(XIAP) and cellular (cIAP1), varied in the literature across
HEK293T (kidney), MDA-MB-231 (breast cancer), and A549
(lung cancer) cells (Figure 5E).68−71 XIAP is known to bind and
inhibit casp-3, -7, and -9 distinctly (Table S2).72,73 Yet, cIAP1
has been characterized to bind, but not inhibit, casp-3, -7,74 and
-9,75 while also inﬂuencing casp-8’s ability to propagate
apoptosis.76 We quantiﬁed levels of XIAP, along with its proapoptotic antagonist second mitochondrial activating factor
(SMAC/Diablo)70,77 and pro-survival protein Bcl-278 in our cell
lines (Figure 5F) and observed that the levels diﬀered slightly
from those reported.68−71 This underscores the importance of
assessing cell death in diﬀerent cell lines, as well as examining the
protein levels in the exact cells being used, to allow meaningful

Activation of Native Caspases Dictates Casp-NG Eﬃcacy for
Inducing Apoptosis

A number of activation and regulation feedback loops have been
reported between the diﬀerent caspases and their pro-survival
partners,33−43 spurring us to examine the mechanisms
contributing to the data observed. For example, casp-7 NG
clearly demonstrated extensive cleavage of PARP-1 (Figure 5A−
C) and cell death (Figure 5G). These data beg the question as to
why exogenously delivered casp-7 is more potent than casp-3,
which shows greater intrinsic catalytic activity (Table S1). To
elucidate mechanistic insights surrounding these ﬁndings, we
tested two hypotheses. The ﬁrst, that the delivered enzymes may
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Figure 6. Executioner casp-NG proteolytic proﬁles after uptake and delivery. (A) Levels of delivered casp-3 and casp-7 do not appear to signiﬁcantly
change in the absence or presence of proteasome inhibitor MG-132 after 24 h incubation in HEK293T cells. Error bars pertain to three independent
biological replicates. (B) Levels of casp-7 remain consistent, in the absence or presence of a proteasome inhibitor, from 4 to 24 h in A549 cells in a single
biological replicate. Proteolytic proﬁles of executioner casp-NG after uptake in whole HEK293T cells; resultant amc/afc ﬂuorescence after treatment
with (C) casp-3 NG, (D) casp-6 NG, and (E) casp-7 NG. (F) Casp-7 NG treatment results in dose-dependent cleavage of endogenous procaspase-3 in
HEK293T cells. (G) Casp-7 NG-induced procaspase-3 cleavage can be observed as a function of time, in the presence or absence of MG-132. (H)
Treatment of casp-3, casp-6, and casp-9cD NGs does not demonstrate signiﬁcant procaspase-7 activation. Proteolytic proﬁles of executioner casp-NG
after uptake in lysed HEK293T cells; resultant amc/afc ﬂuorescence after treatment with (I) casp-3 NG, (J) casp-6 NG, and (K) casp-7 NG. All error
bars correspond to SEM of two independent NG batches, made and tested on separate days.

be degraded upon delivery at distinct rates. The second, that the
delivered caspases are functioning uniquely within the
endogenous caspase pathway; i.e., the less apoptotic cargos are
functioning as single proteases, whereas the more apoptotic

casp-7 cargo may be activiating endogenous caspases. Beginning
with our ﬁrst hypothesis, we assessed delivered casp-3 and casp7 levels (after casp-NG treatment) in the presence or absence of
proteasome inhibitor MG-132.84,85 We observed no statistically
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(Figure S10). Interestingly, casp-3 NG (7-fold) and casp-6 NG
(11-fold) were activated more by the addition of reductant than
was casp-7 NG (3.5-fold), indicating a diﬀerence in redox
sensitivity for the cargos that could correspond to factors such as
active site oxidation or release from the NG. Casp-7 has been
observed to inﬂuence reactive oxygen species production and
accumulation during apoptosis, whereas casp-3 does not,
underlying a distinct redox diﬀerence between the two
DEVDases.40 These data unambiguously indicate that proteolysis and procaspase activation by the various caspase cargos is
directly related to, and could be further improved upon, delivery
vehicle and release compatibility optimization. In summary, we
hypothesize that the phenomenon of casp-7 outperforming
casp-3 may be unique to redox-responsive materials, and
carefully investigating diﬀerent caspase cargos within diﬀerent
delivery systems (redox-responsive and nonredox-responsive)
may be an informative future investigation.
Low levels of endosomal escape routinely hinder delivery
eﬃcacy.87,88 Thus, we hypothesized that if casp-NGs are largely
trapped in endosomes, upon cell lysis, signiﬁcantly more caspase
activity should be observed. To test this hypothesis, we
measured proteolytic activity in lysed cells (workﬂow Figure
S9). When endosomes were disrupted, dramatically more
activity toward multiple substrates was observed upon cell
lysis for all executioner NGs. Casp-3 and casp-6 NGs both
induced ≥20-fold activity toward all four substrates, indicating
that if more casp-3 and -6 NGs escaped the endosome, the
caspase cargos would be appreciably more powerful in activating
endogenous procaspases (Figure 6I,J). On the other hand, lysed
casp-7 NG-treated cells increased cleavage of DEVD-amc 60fold, whereas VEID-afc and LEHD-afc only increased 4-fold
(Figure 6K). Thus, unlike casp-3 and casp-6, which activate
initiator caspases, casp-7-mediated cell death appears to be due
to exogeneous casp-7 activity itself or combined with activation
of executioners procasps-3 and -7 (Scheme 2). In comparing
exogenously delivered casp-3 and casp-7, the diﬀerences in the
initial rate of DEVD-amc cleavage (Figure S11) reﬂect the
intrinsic diﬀerences in catalytic eﬃciency between the two
enzymes (ST 1). Casp-3 NG achieved maximum substrate
turnover within 4 h, whereas casp-7 NG continues to increase
over several days, consistent with the distinct enzymatic
eﬃciencies of the two DEVDases.56 These data suggest that
there is merit for further investigations of the diﬀerent apoptotic
cargos as there may be diﬀerences in apoptotic time scales and
the background of apoptosis inhibitors in various cells which
could result in more tunable therapeutics. Moreover, these data
demonstrated that if more endosomal escape is achieved, the
executioner casp-NG can clearly feedback more eﬀectively to
propagate caspase activation.

signiﬁcant proteasomal degradation of delivered casp-3 or casp7, as assessed by MG-132-based inhibition of the proteasome
(Figure 6A). To more robustly address the inﬂuence of MG-132
on casp-7, we directly monitored cleaved casp-7 levels in A549
cells over time and, again, observed no evidence of signiﬁcant
proteasomal degradation (Figure 6B). These data suggest that
casp-3 and casp-7 are not degraded by the proteasome at
statistically diﬀerent rates upon exogenous introduction.
Next, to assess which caspases have been activated, after caspNG treatment, cells were harvested and then subjected to
incubation with ﬂuorogenic peptide substrates (workﬂow in
Figure S9). The ﬂuorogenic peptide substrates used include
DEVD-amc (casp-3/-7), VEID-afc (casp-6), LEHD-afc (casp-8
and -9), and LETD-afc (casp-8).86 Cleavage of peptide
substrates could be clearly observed after NG treatment.
Casp-3/-7 substrate DEVD-amc was cleaved approximately 2fold above baseline levels upon treatment with casp-3 NG
(Figure 6C). However, a similar level of ﬂuorescence was also
visualized for VEID and LEHD substrates after casp-3 NG
treatment, indicating that casp-3 activated some endogeneous
procasp-6 and procasp-8/-9 (Table S3 and Scheme 2). Casp-6
NG treatment also demonstrated a 2-fold increase in proteolytic
activity toward casp-6 substrate VEID (Figure 6D), consistent
with casp-6 NG-induced cleavage of DVL3 (Figure 5D).60 More
signiﬁcantly, casp-6 NG demonstrated a 5-fold increase in
activity of casp-8/9 substrate LEHD, suggesting that casp-6
activated procaspase-8 and/or -9 (Table S3 and Scheme 2). Due
to the known activation of casp-8 by casp-6,32 we hypothesize
that casp-8 is most likely responsible for the observed LEHDase
activity. Lastly, casp-7 NG treatment demonstrated a 10-fold
increase in intracellular activity toward DEVD-amc (Figure 6E).
This activity is the result of the exogeneously delivered casp, but
also may reﬂect the activity of endogeneous procasp-3 and/or -7
that has been activated by delivered casp-7. Although it is
impossible to detect endogenously cleaved casp-7 upon
recombinant casp-7 delivery, we were able to observe dosedependent cleavage of endogenous casp-3 (Figure 6F), in the
presence or absence of MG-132, a proteasome inhbitor (Figure
6G). These data clearly indicate that the signiﬁcant DEVD-amc
proteolysis observed upon casp-7 NG treatment (Figure 6E) is
representative of caspase feedback loops activating endogenous
procasp-3. On the other hand, and in accordance with the lower
levels of DEVD-amc proteolysis observed by casp-3 NG (Figure
6C), casp-3 NG did not result in noticeable cleavage of
endogeneous procaspase-7 (Figure 6H). Overall, the observed
activation of caspases appears to be in line with known caspase
activation pathways (Scheme S1) and correlates well with the
observed levels of cell death (Figure 5G).
While levels of cell death correlated with caspase activities, we
sought to determine whether caspases were fully released or
whether both activities could be increased by additional caspase
release in the cytosol. As our NGs are redox-responsive, we
typically assessed caspase activity in the absence of added
reductant to ensure that the activity evaluated is from
cytosolically disassembled casp-NG. Nevertheless, additional
reductant would (i) maximize caspase activity by ensuring
reduction of the caspases’s catalytic cysteine residue and (ii)
may also elucidate if casp-NG have reached the cytosol but fail to
disassemble/release the protein. Upon the addition of 0.5 mM
DTT, we observed higher levels of ﬂuorogenic peptide
proteolysis for casp-3-NG-treated cell lysates toward DEVD
substrate, casp-6-NG toward DEVD/VEID/LEHD/LETD
substrates, and casp-7 toward DEVD/VEID/LEHD substrates

■

CONCLUSIONS AND OUTLOOK
Cancers from diﬀerent organs and disease stages are known to
overexpress pro-survival proteins to diﬀerent extents.69,89−91
This ﬁnding underscores the need for personalized medicine,
which recognizes the central importance of tailoring a speciﬁc
therapy to individual disease variants. Pro-apoptotic proteins,
such as caspases, oﬀer the opportunity to exogenously overcome
unique apoptosis desensitization phenotypes in various cancers.
Being a native cellular component, caspases have the advantage
of being active only in their targeted microenvironment, thus
providing inherent selectivity. However, prior to this work,
which initiator or executioner caspases would be most eﬀective
in inducing apoptosis when introduced exogenously remained
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apoptotic pathway, delivering full-length casp-8 with the DED
domain may better facilitate propagation of apoptosis via the
DISC which is not mediated by the DED-deleted casp-8 used
herein. Casp-6 NGs induced levels of cell death comparable to
those of casp-3, but most importantly, casp-6 induced the most
LEHDase activity, suggesting the most procasp-8 and -9
activation in cellulo (Table S3 and Scheme 2). In summary,
these data strongly indicate that various caspases, particularly
casp-7 and casp-9, eﬀectively induce apoptosis with signiﬁcant
therapeutic potential. Moreover, these results suggest that the
use of particular caspases, perhaps complimented with other
pro-apoptotic factors, may allow optimal cell killing in various
disease states, such as cancers, each with their own unique antiapoptotic status (Scheme 2).
In the ﬁeld of delivery, diﬀerent delivery vehicles are often
compared. Yet, comparing distinct cargo, even members of the
same family, is often overlooked due to formulation limitations.
Here, for the ﬁrst time, direct comparison of diﬀerent apoptotic
caspases as apoptotic cargos was assessed. Although there may
be some inﬂuence on the chemistries of the materials used for
exogenous introduction, this study demonstrates the clinical
potential of caspases other than casp-3 to induce apoptosis. The
mechanistic ﬁndings herein show that judicious matching of the
target cells and the functional cargo enable us to maximize
therapeutic eﬃcacy. In future systems, caspases can be
combined with chemotherapeutics to maximize endogenous
caspase activation or with pro-survival antagonists to relieve
diseased interactions or prevent inhibition of the delivered
cargo. Moreover, speciﬁc caspases and/or combinations may
now be tailored to particular tissue types to overcome disease
characteristics and shift the equilibrium to favor death.

completely unknown. A number of prior reports underscore the
fact that each caspase is uniquely regulated and is subject to
inactivation by diﬀerent factors.74,78,92−95 Furthermore, various
cell lines (our somewhat simplistic proxy for diﬀerent disease
variants in this study) display diﬀerent levels of caspase
inhibitors and other anti-apoptotic (proliferative) elements
(Scheme 2). These two factors together suggest that various cell
lines with their unique suite of overexpressed anti-apoptotic
factors (Figure 5E,F) might be diﬀerentially susceptible to the
induction of apoptosis.
To explore that hypothesis, casp-3, -6, -7, -8, and -9 were
successfully encapsulated within nanogels and were delivered
intracellularly, demonstrating varying levels of proteolysis in
vitro and in cellulo (Table S3). We hypothesize that uptake and
endosomal escape are dominated by the properties of the
polymer used for encapsulation and delivery. Because the same
polymer was used to deliver all caspases, diﬀerences in apoptotic
eﬃcacy should be attributed to (i) the eﬀect of NG formation on
enzymatic activity and function, (ii) the inherent catalytic
properties of each caspase in the cytosol at the resultant
concentration, and (iii) the environment various caspases
encounter in diﬀerent cell lines or subcellular locations.
Formation of these NGs was straightforward and reproducible.
Thus, we envision that the required polymeric components
could be packaged and distributed for widespread use within the
research community for exogenous introduction of many
cysteine-containing protein cargos.
It is critical to note that while all caspases were eﬀectively
encapsulated and delivered in an active form, not all caspases
showed the same propensity to induce cell death. Casp-7 and
casp-9cD stood out as the most potent apoptosis inducers in
several assays, showing even greater apoptosis-inducing
potential than that with casp-3 (Table S3). Casp-3 is the family
member with the highest enzymatic eﬃciency,45,56 widest
substrate pool,7,48,86 and its activation unambiguously correlates
with eﬃcient apoptosis in numerous cancer cells upon a myriad
of stimuli (e.g., drugs).34−36,40,44 These data imply that the
alterations to pro-survival elements may have been adopted as a
forceful strategy to block casp-3 activity, thus making casp-7 and
-9 better situated to induce apoptosis in those cells.
The observed diﬀerence of casp-3 and -7 to induce cell death
was striking given that casp-3 and casp-7 are similar executioner
DEVDases. This may also suggest that distinct diﬀerences in
mechanisms of their inhibition (i.e., phosphorylation94 or metal
binding,92 Table S2) may impact their death-inducing potential
(Scheme 2). Furthermore, as we observed that the addition of
exogeneous reductant inﬂuenced in cellulo caspase proteolytic
activity, it is possible that the ﬁndings herein are unique to redoxresponsive delivery systems. On the other hand, casp-3 may be
more susceptible to oxidation or other cysteine blocking
mechanisms than casp-7 (i.e., glutathionylation,95 Table S2).
Echoing the conventional wisdom of the hierarchical caspase
pathway, and in agreement with the vast apoptotic literature, we
conclude that maximal apoptosis is observed upon caspase
feedback loops activating procasp-3 or relieving active casp-3
inhibition.35,36,44,96 The exogenous introduction of casp-7
demonstrated high levels of apoptosis due to endogenous
procaspase-3 activation. Therefore, in cell lines with apoptoticresistant phenotypes, wherein casp-3 activity is often compromised, targeting casp-7 or points upstream of casp-3 inhibition
should be explored as strategies to push diseased cells to die.
The only caspase that failed to induce cell death was casp-8
(Table S3). To take advantage of casp-8’s role in the extrinsic

■

MATERIALS AND METHODS

Caspase Random Copolymer NG Formation
Procedures for casp-NG formation were followed similarly to those
previously described for casp-NG.10 Twenty mg of random PEG−PDS
was added to a vial and dissolved in 1 mL of 1× PBS, pH 7.4, via
sonication for a ﬁnal concentration of 20 mg/mL polymer. This
polymer stock solution was stirred at 4 °C for ∼1 h before 0.5 mL was
aliquoted into a new vial. To the 10 mg polymer aliquot was added a
solution (containing casp-3, casp-6, casp-7, casp-8, or casp-9) at a
weight ratio of 25:1 polymer/protein with additional 1× PBS to achieve
a ﬁnal concentration of 10 mg/mL (or a ﬁnal volume of 1 mL). The
polymer−protein solution was left to stir for ∼3 h at 4 °C. The
conjugates were then cross-linked with dithiothreitol and additional
stirring for ∼1 h at 4 °C. The NG conjugates were then puriﬁed via
dialysis against 1× PBS, pH 7.4 using a 100k MWCO aqueous
membrane for ∼20 h at 4 °C with multiple buﬀer changes. Dialysis
against this large membrane allows removal of the cross-linking
byproduct pyridine-2-thiol, DTT, and unencapsulated protein. Prior to
dialysis, cross-linking and functionalization were quantiﬁed using 2 μL
of the NG solution + 98 μL of water ± excess DTT and recording the
absorbance of the cross-linking byproduct at 343 nm using UV−vis
spectroscopy.

Assessing Activity of NG-Released Caspase Using
Fluorogenic Peptide Substrates
For a control to assess loss of caspase activity, during NG formation, the
corresponding caspases were diluted to 12 μM and stored in 1× PBS,
pH 7.4 at 4 °C for the same amount of time as NG formation + dialysis
procedure. After dialysis, two samples of puriﬁed casp-NG were diluted
in the corresponding caspase activity buﬀer in the presence of DTT or
water to release or maintain entrapment of the encapsulated protein. In
the same 96-well plate, the control free protein (stored at 4 °C for ∼24
h) was diluted similarly based on the amount of NG protein in the
sample (calculated using NG encapsulation eﬃciency). After a 10 min
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NG-Released Caspase Activity toward Protein Substrates in
Lysate

incubation, a volume of each reaction was added using a multichannel
pipet to wells containing the corresponding substrate in DMSO. The
activity in each of the samples was immediately measured in duplicate
over a time course at 37 °C as the increase in ﬂuorescence of cleaved
coumarin measured in a Spectramax M5 spectrometer (Molecular
Devices, excitation 365 nm; emission 495 nm for amc; excitation 380
nm, and emission 510 for afc). The initial velocity, in relative
ﬂuorescence units/s (RFU/s), was reported and normalized to the
control with unencapsulated protein. The graphs included in Figure 3
correspond to three individual biological replicates performed on three
separate days with individual NG batches. Casp-3 activity buﬀer: 20
mM HEPES pH 7.5, 150 mM NaCl, CaCl2, 10% PEG 400; substrate:
N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-amc,
Enzo Life Sciences). Casp-3 assay conditions: 50 μL of reaction
mixture added to 5 μL of 0.5 μM substrate. Casp-6 activity buﬀer: 100
mM HEPES, pH 7.5, 100 mM NaCl, 10% sucrose, 0.1% CHAPS;
substrate: N-acetyl-Val-Glu-Ile-Asp-7-amino-4-methylcoumarin
(VEID-afc, Enzo Life Sciences). Casp-6 assay conditions: 50 μL of
reaction mixture added to 5 μL of 0.5 μM substrate. Casp-7 activity
buﬀer: 100 mM HEPES, pH 7.5, 5 mM CaCl2, 10%, PEG 400, 0.1%
CHAPS, substrate: N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-amc, Enzo Life Sciences). Casp-7 assay conditions: 50
μL of reaction mixture added to 5 μL of 0.5 μM substrate. Casp-8
activity buﬀer: 10 mM PIPES, pH 7.2, 100 mM NaCl, 1 mM EDTA,
0.05% CHAPS, 10% sucrose; substrate: N-acetyl-Leu-Glu-His-Asp-7amino-4-methylcoumarin (LEHD-afc, Enzo Life Sciences, LETD-afc,
was also tested). Casp-8 assay conditions: 50 μL of reaction mixture
added to 10 μL of 0.5 μM substrate. Casp-9 activity buﬀer: 100 mM
MES, pH 6.5, 10% PEG 8000; substrate: N-acetyl-Leu-Glu-His-Asp-7amino-4-methylcoumarin (LEHD-afc, Enzo Life Sciences). Casp-9
assay conditions: 100 μL of reaction mixture added to 10 μL of 0.5 μM
substrate.

To a solution of puriﬁed casp-NG (100 μL, 7 mg/mL), 20 μL of 1 M
DTT or water was added to release or maintain entrapment of the
encapsulated protein. After a 10 min incubation, 30 μL of these
solutions were added to 60 μL of homogeneous cell lysate (HEK,
Jurkat, or MDA-MB-231) and 20 μL of the corresponding caspase
activity assay buﬀer. The zero time point was immediately taken by
removing 30 μL of this solution and mixing it with 10 μL of SDS-PAGE
3× dye (with reductant) and immediately heated at 95 °C for ∼5 min.
The remaining reaction was left to incubate at 37 °C for several hours.
After incubation, the ﬁnal time point was taken identically and samples
were assayed by Western Blot.

Adherent Mammalian Cell Studies for Delivery Evaluation
by Western Blot
Brieﬂy, all adherent cells were grown in 100 mm × 15 mm tissue culture
dishes in the presence of DMEM (Gibco, Thermo Fisher)
supplemented with 10% FBS (Gibco, Thermoﬁsher) and 1%
penicillin/streptomycin (Gibco, Thermo Fisher) at 37 °C, 5% CO2
until ready for use. Two days prior to cellular assessment, cells were
plated at a density of ∼5 × 104 in a 24-well plate and left to adhere for
∼24 h. The day before the assay, puriﬁed NG samples were diluted in
the appropriate cell culture media with 10% 1× PBS. Plates were then
left to incubate. After incubation, cells were washed twice with 1× PBS
(Gibco, Thermo Fisher) and then lysed with 60 μL of freshly prepared
and sterile ﬁltered lysis buﬀer. Lysis buﬀer contained 50 mM Tris, pH
8.0, 150 mM NaCl, 1% Triton-X 100 and 10 mM DTT with 1× halt
protease/phosphatase inhibitor cocktail (Pierce, Thermo Fisher).
Culture plates were incubated at 4°C for 25 min with constant
rotation. Lysates were then extracted and clariﬁed by centrifugation for
20 min at 16,000g, 4°C.

Suspension Mammalian Cell Studies for Delivery
Evaluation by Immunoblot

Immunoblotting

Brieﬂy, Jurkat cell suspensions were cultured in T75 ﬂasks in RPMI
1640 media (Genesee Scientiﬁc) supplemented with 10% FBS (Gibco,
Thermo Fisher) and 1% penicillin/streptomycin (Gibco, Thermoﬁsher) at 37 °C, 5% CO2. The day prior to cellular assessment, cells
were plated at a density of ∼1 × 105 in a 24-well plate in the presence of
PBS containing NG samples, composing 10% of the ﬁnal solution
volume. Plates were then left to incubate. After incubation, the cell
suspensions were harvested by centrifugation at 4000g for 5 min.
Medium was carefully decanted, and cells were lysed on ice by
incubation with 60 μL of freshly prepared and sterile ﬁltered lysis buﬀer.
Lysis buﬀer contained 50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton-X
100, and 10 mM DTT with 1× halt protease/phosphatase inhibitor
cocktail (Pierce, Thermoﬁsher). Lysates were then clariﬁed by
centrifugation for 20 min at 16,000g, 4°C.

Lysates were assayed for the total protein concentration using the
bicinchoninic acid assay (Pierce). Lysates were diluted to attain
identical protein concentrations in each sample, and SDS-PAGE
samples were immediately diluted into denaturing, reducing sample
buﬀer and heated to 95 °C for ∼10 min. Twenty μL of lysate samples
were loaded into a 16% SDS-PAGE, and electrophoresis was executed
at 175 V for 70 min. Samples were then transferred to a PVDF
membrane (Millipore) at 100 V for 140 min, with two ice block
changes. After transfer, membranes were blocked using OneBlock
Western-CL blocking buﬀer (Genesee Scientiﬁc) for 60 min at room
temperature and then cut into appropriate molecular weight ranges to
probe for speciﬁc proteins. Membranes were incubated with the
primary antibody overnight at 4°C with constant rotation. Primary
antibodies, purchased from Cell-Signaling Technologies, were used at a
1:1000 dilution including anti-α-tubulin (#2144S), anti-His
(#12698S), anti-cleaved casp-8 (#9748S), anti-PARP (#9532S), anticleaved PARP (#9541S), anti-casp-3 (#9662S), anti-casp-6 (#9762S),
anti-casp-7 (#9492S), anti-DVL3 (#3218S), anti-DJ-1 (#2134S), antiXIAP (#14334S), and anti-cleaved lamin A (#2035S). Primary
antibodies purchased from Santa Cruz Biotechnology were used at a
1:200−1000 dilution including anti-Bcl-2 (SC-7382), anti-BID (SC373939), and anti-p23 (SC-101496). Finally, a SMAC/Diablo
antibody was purchased from Novus Biologicals (#56311SS) and was
used at a 1:250 dilution. Membranes were then washed with 1× TBST
three times for 10 min each and then probed with a secondary goat antirabbit HRP antibody (#20-303, Genesee Scientiﬁc) or goat anti-mouse
HRP antibody (Jackson AﬃniPure115-035-003) at 1:20,000 dilution
for 1 h at room temperature. Membranes were then washed again with
1× TBST three times for 10 min each followed by incubation with
SuperSignal West Duration substrate (#34075, Thermo Fisher) for 2−
3 min at room temperature and imaged using the ChemiDoc MP
imaging system (BioRad). Blots were quantiﬁed using ImageJ and
normalized to the α-tubulin loading control.

Apoptosis Evaluation Using Flow Cytometry and
7-Aminoactinomycin D
7-AAD can be utilized to distinguish viable, apoptotic, and late
apoptotic/dead cells using ﬂow cytometry.79,80 For adherent cells, after
incubation of NG-cell culture 24-well plates, the medium containing
detached cells was aspirated and placed in a tube. The remaining
adhered cells were not further washed in an eﬀort to save any remaining
loosely detached (apoptotic) cells. One hundred μL of 1× trypsin
(Sigma) was then added and left to incubate for ∼5 min at 37 °C in 5%
CO2 until all cells were visibly removed from the plate. The 100 μL
trypsin/cell solution was removed and added to tubes containing the
corresponding aspirated medium. The tubes were then centrifuged at
4000g for 5 min to pellet all cells. The supernatant was removed,
carefully leaving the cell pellet intact. Two hundred microliters of FACS
buﬀer (sterile ﬁltered 0.5% BSA (#9048-46-8) in 1× PBS, pH 7.4)
prepared with 10 μg/mL fresh 7-aminoactinomycin D (7-AAD) was
added, and the pellet was gently redispersed via pipetting. Samples were
immediately assayed by ﬂow cytometry using a 640 nm laser line. For
analysis, cells were gated for live vs apoptotic vs late apoptotic/dead
populations (FSC-A vs 7-AAD-A).79 For suspension cells, when time
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elapsed for NG cell culture incubation within 24-well plates, the cell
suspension was harvested by centrifugation at 4000g for 5 min to pellet
all cells. Then, an identical procedure to that for adherent cells was
followed.

■

Apoptosis Evaluation Using AnnexinV

study); supplemental Figures S1−S11, Tables S1−S3 and
Scheme S1 (PDF)
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Adherent and suspension cells were harvested identically to the ﬂow
cytometry procedures described above, in which cells were cultured in
6-well plates. After pelleting all cells, cells were washed twice via
redispersion in 500 μL of a buﬀer composed of 20 mM HEPES (pH
7.5), 10% glycerol, 0.5 mM EDTA, followed by centrifugation. After
two washes, the cell pellets were redispersed in 2250 μL of FACS buﬀer.
This reaction was then aliquoted (500 μL each for four substrates) in
the presence of 20 μM of one ﬂuorogenic caspase substrate (see
Supporting Information for details related to DEVD-amc, VEID-afc,
LETD-afc, IETD-afc, or LEHD-afc). Technical replicates (200 μL
each) were plated in tissue culture treated 96-well plates (with top) and
left to incubate at 37 °C, 5% CO2, by reading the plate over time. To
prevent evaporation, 100 μL of PBS was added to the surrounding wells.
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caspase, casp, cysteine aspartate protease; NG, nanogel; BCL-2,
B-cell lymphoma-2; IAP, inhibitors of apoptotic proteins; TNF,
tumor necrosis factor; DED, death eﬀector domain; DISC,
death-inducing signaling complex; Apaf-1, apoptotic protease
activating factor-1; CARD, caspase activation and recruitment
domain; ISL, intersubunit linker; WT, wild-type; CT,
constitutively two chain; LG, caspase large subunit; SM, caspase
small subunit; pro, caspase prodomain; DTT, dithiothreitol;
PEG, polyethylene glycol; PDS, pyridyl disulﬁde; PEG−PDS,
polymer of PEG and PDS; 7-AAD, 7-aminoactinomycin; PBS,
phosphate-buﬀered saline; SDS-PAGE, sodium dodecyl sulfatepolyacrylamide gel electrophoresis; GSH, glutathione; casp-9cD,
constitutively dimeric casp-9; casp-7HC, handcuﬀed casp-7;
PARP-1, poly(ADP-ribose) polymerase 1; DVL3, disheveled
segment polarity protein 3; PARK7 or DJ-1, Parkinson’s disease
protein 7; BID and tBID (truncated BID), BH3 interactingdomain death agonist; HeLa-deGFP, HeLa cells expressing
destabilized GFP

In Cellulo Assessment of Uptaken Casp-NG Activity Using
Fluorogenic Peptide Substrates (Cells Lysed after
Treatment)
For ﬂuorogenic peptide substrate analysis of NG-treated lysates, cells
were grown in 6-well plates (100,000 cells/mL adherent; 200,000 cells/
mL suspension) and treated with 0.75 mg/mL NG and then separated
for the diﬀerent substrates. After 24 h, adherent and suspension cells
were harvested and lysed (300 μL of lysis buﬀer without protease
inhibitor cocktail) similarly to preparations for Western blot analysis.
After clarifying lysates, 30 μL of lysate was aliquoted in a new tube in the
presence of 500 μL of general protease assay buﬀer (20 mM HEPES
(pH 7.5), 10% glycerol, 0.5 mM EDTA) with 5 mM DTT and 20 μM of
the relevant ﬂuorogenic peptide substrates as above. Technical
replicates (200 μL each) were plated in black 96-well plates, sealed,
and incubated at 37 °C, 5% CO2, by monitoring ﬂuorescence as a
function of time over 48 h.
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